Intellia Therapeutics (NTLA) Short Interest Ratio & Short Volume $12.17 -0.08 (-0.65%) Closing price 04:00 PM EasternExtended Trading$12.12 -0.05 (-0.41%) As of 06:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Intellia Therapeutics Short Interest DataIntellia Therapeutics (NTLA) has a short interest of 24.06 million shares. This marks a 0.00% change in short interest from the previous month. The short interest ratio (days to cover) is 8.7, indicating that it would take 8.7 days of the average trading volume of 3.25 million shares to cover all short positions.Current Short Interest24,060,000 sharesPrevious Short Interest24,060,000 sharesChange Vs. Previous MonthNo ChangeDollar Volume Sold Short$248.30 millionShort Interest Ratio8.7 Days to CoverLast Record DateJanuary 31, 2025Outstanding Shares101,850,000 sharesPercentage of Shares Shorted23.62%Today's Trading Volume4,444,535 sharesAverage Trading Volume3,253,526 sharesToday's Volume Vs. Average137% Short Selling Intellia Therapeutics? Sign up to receive the latest short interest report for Intellia Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNTLA Short Interest Over TimeNTLA Days to Cover Over TimeNTLA Percentage of Float Shorted Over Time Intellia Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 1/31/202524,060,000 shares $248.30 million No ChangeN/A8.7 $10.32 1/15/202524,060,000 shares $233.62 million +11.0%N/A8.2 $9.71 12/31/202421,670,000 shares $252.67 million +9.4%N/A7.9 $11.66 12/15/202419,810,000 shares $255.55 million +4.8%N/A7.9 $12.90 11/30/202418,910,000 shares $295.37 million +15.5%N/A7.8 $15.62 11/15/202416,370,000 shares $228.69 million +1.4%N/A7.2 $13.97 10/31/202416,150,000 shares $229.65 million -1.3%N/A8.5 $14.22 10/15/202416,360,000 shares $319.35 million +8.1%N/A11.2 $19.52 9/30/202415,140,000 shares $311.13 million +2.6%N/A10.5 $20.55 9/15/202414,760,000 shares $325.75 million +7.7%N/A9.7 $22.07 Get the Latest News and Ratings for NTLA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Intellia Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/31/202413,700,000 shares $307.43 million -0.9%N/A9.3 $22.44 8/15/202413,820,000 shares $316.06 million +3.4%N/A8.4 $22.87 7/31/202413,370,000 shares $350.43 million -3.5%N/A8 $26.21 7/15/202413,850,000 shares $360.24 million +4.5%N/A8.4 $26.01 6/30/202413,250,000 shares $296.54 million -3.6%N/A8.4 $22.38 6/15/202413,740,000 shares $345.56 million -6.5%N/A9.4 $25.15 5/31/202414,700,000 shares $314.29 million -3.1%N/A10.4 $21.38 5/15/202415,170,000 shares $397.76 million -1.8%N/A10.7 $26.22 4/30/202415,440,000 shares $330.42 million +5.8%N/A10.5 $21.40 4/15/202414,590,000 shares $334.40 million -1.6%N/A9.5 $22.92 3/31/202414,830,000 shares $407.97 million +9.9%N/A9.6 $27.51 3/15/202413,500,000 shares $382.05 million +7.0%N/A8.6 $28.30 2/29/202412,620,000 shares $405.35 million +8.5%N/A7.6 $32.12 2/15/202411,630,000 shares $331.11 million +6.0%N/A7.5 $28.47 1/31/202410,970,000 shares $261.31 million +5.0%N/A7.1 $23.82 1/15/202410,450,000 shares $289.15 million +2.9%N/A6.8 $27.67 12/31/202310,160,000 shares $309.78 million -3.2%N/A6.8 $30.49 12/15/202310,500,000 shares $323.19 million +6.6%N/A7.2 $30.78 11/30/20239,850,000 shares $291.86 million +4.0%N/A7.6 $29.63 11/15/20239,470,000 shares $251.71 million -1.7%N/A8 $26.58 10/31/20239,630,000 shares $241.23 million +18.6%N/A9.7 $25.05 10/15/20238,120,000 shares $242.22 million -1.1%N/A9.7 $29.83 9/30/20238,210,000 shares $259.60 million +6.2%N/A10.3 $31.62 9/15/20237,730,000 shares $276.89 million -1.4%N/A10 $35.82 8/31/20237,840,000 shares $293.84 million +7.5%N/A9.4 $37.48 8/15/20237,290,000 shares $282.92 million +13.9%N/A8.1 $38.81 7/31/20236,400,000 shares $270.91 million +3.1%N/A6.7 $42.33 7/15/20236,210,000 shares $272.99 million +2.5%N/A6.3 $43.96 6/30/20236,060,000 shares $247.13 million +5.4%N/A5.9 $40.78 6/15/20235,750,000 shares $262.03 million +9.7%N/A5.6 $45.57The FED is losing the war on inflation (Ad)It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…You can go here to give yourself a head start. 5/31/20235,240,000 shares $195.24 million -11.8%N/A5 $37.26 5/15/20235,940,000 shares $271.81 million -13.0%N/A5.4 $45.76 4/30/20236,830,000 shares $257.83 million -2.0%N/A6.3 $37.75 4/15/20236,970,000 shares $265.98 million -6.1%N/A6.2 $38.16 3/31/20237,420,000 shares $276.54 million -5.8%N/A6.5 $37.27 3/15/20237,880,000 shares $322.13 million -2.7%N/A6.8 $40.88 2/28/20238,100,000 shares $325.38 million +6.6%N/A6.5 $40.17 2/15/20237,600,000 shares $317.53 million +3.4%N/A6.3 $41.78 1/31/20237,350,000 shares $311.93 million +12.0%N/A6.1 $42.44 1/15/20236,560,000 shares $246.92 million -1.1%N/A5.7 $37.64 12/30/20226,630,000 shares $231.32 million +11.4%N/A6 $34.89 12/15/20225,950,000 shares $217.35 million -1.2%N/A5.4 $36.53 11/30/20226,020,000 shares $309.79 million -9.5%N/A5.2 $51.46 11/15/20226,650,000 shares $351.92 million -5.1%N/A6.7 $52.92 10/31/20227,010,000 shares $369.99 million +6.5%N/A6.7 $52.78 10/15/20226,580,000 shares $344.59 million -4.2%N/A5.8 $52.37 9/30/20226,870,000 shares $384.45 million +2.8%N/A5.9 $55.96 9/15/20226,680,000 shares $458.11 million -2.8%N/A5.2 $68.58 8/31/20226,870,000 shares $412.61 million -1.4%N/A5.5 $60.06 8/15/20226,970,000 shares $476.89 million +3.4%10.2%5.4 $68.42 7/31/20226,740,000 shares $436.48 million -6.7%9.9%5 $64.76 7/15/20227,220,000 shares $456.88 million -3.5%10.6%5.6 $63.28 6/30/20227,480,000 shares $387.16 million +7.0%11.0%5.9 $51.76 6/15/20226,990,000 shares $286.10 million +5.4%10.3%5.9 $40.93 5/31/20226,630,000 shares $305.91 million -4.6%9.8%6.2 $46.14 5/15/20226,950,000 shares $337.77 million +11.4%10.2%5.8 $48.60 4/30/20226,240,000 shares $305.95 million +9.9%9.3%5.5 $49.03 4/15/20225,680,000 shares $340.40 million +1.1%8.5%5 $59.93 3/31/20225,620,000 shares $408.41 million +4.5%8.4%4.8 $72.67 3/15/20225,380,000 shares $313.49 million +1.5%8.0%4.8 $58.27 2/28/20225,300,000 shares $523.91 million +7.3%7.9%4.9 $98.85 2/15/20224,940,000 shares $486.69 million +2.9%7.4%5.2 $98.52 1/31/20224,800,000 shares $453.94 million +10.3%7.2%5.4 $94.57 1/15/20224,350,000 shares $397.46 million +1.9%6.5%5.4 $91.37 12/31/20214,270,000 shares $504.88 million -7.4%6.4%6 $118.24 12/15/20214,610,000 shares $563.80 million +16.1%6.9%6.2 $122.30 11/30/20213,970,000 shares $456.59 million +14.4%5.9%5.4 $115.01 11/15/20213,470,000 shares $463.38 million +4.8%5.2%4.6 $133.54 10/29/20213,310,000 shares $440.16 million -10.3%5.0%4.3 $132.98 10/15/20213,690,000 shares $481.51 million +5.7%5.6%4.1 $130.49 9/30/20213,490,000 shares $468.18 million -0.6%5.3%3.5 $134.15 9/15/20213,510,000 shares $528.04 million +2.3%5.3%1.7 $150.44 8/31/20213,430,000 shares $550.62 million -3.7%5.2%1.6 $160.53 8/13/20213,560,000 shares $553.19 million -2.2%5.4%1.6 $155.39 7/30/20213,640,000 shares $516.33 million +7.1%5.5%1.6 $141.85 7/15/20213,400,000 shares $469.54 million -26.6%5.2%1.5 $138.10 6/30/20214,630,000 shares $749.64 million -23.6%7.1%2.1 $161.91 6/15/20216,060,000 shares $537.22 million -7.3%10.1%4.7 $88.65 5/28/20216,540,000 shares $490.11 million -1.5%10.9%5.4 $74.94 5/14/20216,640,000 shares $404.24 million +0.5%N/A4.9 $60.88The FED is losing the war on inflation (Ad)It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…You can go here to give yourself a head start. 4/30/20216,610,000 shares $529.33 million -9.3%N/A4.7 $80.08 4/15/20217,290,000 shares $556.59 million -14.4%N/A4.8 $76.35 3/31/20218,520,000 shares $615.48 million -2.5%N/A5.2 $72.24 3/15/20218,740,000 shares $572.64 million +8.0%N/A5 $65.52 2/26/20218,090,000 shares $464.93 million -5.6%N/A4.5 $57.47 2/12/20218,570,000 shares $590.64 million -9.3%N/A5.1 $68.92 1/29/20219,450,000 shares $604.52 million -2.3%N/A5.7 $63.97 1/15/20219,670,000 shares $805.51 million -4.7%N/A6.2 $83.30 12/31/202010,150,000 shares $574.29 million -8.1%N/A7.1 $56.58 12/15/202011,040,000 shares $575.18 million -5.6%N/A9 $52.10 11/30/202011,700,000 shares $460.75 million -7.1%N/A10.6 $39.38 11/15/202012,590,000 shares $418.37 million -2.3%N/A13 $33.23 10/30/202012,890,000 shares $321.61 million +0.8%N/A14.4 $24.95 10/15/202012,790,000 shares $316.04 million +7.1%N/A14.7 $24.71 9/30/202011,940,000 shares $237.37 million +7.1%N/A14.8 $19.88 9/15/202011,150,000 shares $248.31 million +2.5%N/A13.9 $22.27 8/31/202010,880,000 shares $234.79 million -0.7%N/A13.8 $21.58 8/14/202010,960,000 shares $217.99 million +1.8%N/A11.8 $19.89 7/31/202010,770,000 shares $191.81 million +0.8%N/A10.7 $17.81 7/15/202010,680,000 shares $237.95 million -4.5%26.0%10.8 $22.28 6/30/202011,180,000 shares $228.30 million +11.5%28.0%11.4 $20.42 6/15/202010,030,000 shares $193.98 million -7.2%25.1%10.9 $19.34 5/29/202010,810,000 shares $189.28 million +2.0%24.4%11.5 $17.51 5/15/202010,600,000 shares $187.20 million +2.2%26.5%12.5 $17.66 4/30/202010,370,000 shares $139.68 million -3.5%26.1%13.6 $13.47 4/15/202010,750,000 shares $138.25 million +3.2%27.5%14.2 $12.86 3/31/202010,420,000 shares $151.92 million -2.2%26.6%13.8 $14.58 3/13/202010,656,600 shares $139.07 million +1.3%34.5%10.6 $13.05 2/28/202010,520,000 shares $126.13 million +1.4%34.1%15.5 $11.99 NTLA Short Interest - Frequently Asked Questions What is Intellia Therapeutics' current short interest? Short interest is the volume of Intellia Therapeutics shares that have been sold short but have not yet been closed out or covered. As of January 31st, investors have sold 24,060,000 shares of NTLA short. Learn More on Intellia Therapeutics' current short interest. What is a good short interest ratio for Intellia Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NTLA shares currently have a short interest ratio of 9.0. Learn More on Intellia Therapeutics's short interest ratio. Which institutional investors are shorting Intellia Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Intellia Therapeutics: Wolverine Trading LLC, Group One Trading LLC, D. E. Shaw & Co. Inc., Caption Management LLC, Citadel Advisors LLC, Susquehanna International Group LLP, Concourse Financial Group Securities Inc., PEAK6 LLC, Walleye Capital LLC, Simplex Trading LLC, and FNY Investment Advisers LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. How does Intellia Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Intellia Therapeutics: SpringWorks Therapeutics, Inc. (19.36%), Biohaven Ltd. (9.34%), Recursion Pharmaceuticals, Inc. (19.74%), PTC Therapeutics, Inc. (5.39%), Organon & Co. (6.46%), Ultragenyx Pharmaceutical Inc. (4.51%), Alvotech (0.37%), Avidity Biosciences, Inc. (12.53%), ADMA Biologics, Inc. (5.58%), Arcellx, Inc. (18.01%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: AppLovin Co. ($5.21 billion), Charter Communications, Inc. ($4.07 billion), Reddit, Inc. ($3.33 billion), The Kroger Co. ($2.67 billion), Cencora, Inc. ($2.29 billion), Hims & Hers Health, Inc. ($2.17 billion), SoFi Technologies, Inc. ($1.99 billion), Live Nation Entertainment, Inc. ($1.87 billion), Rivian Automotive, Inc. ($1.76 billion), and Moderna, Inc. ($1.60 billion). View all of the most shorted stocks. What does it mean to sell short Intellia Therapeutics stock? Short selling NTLA is an investing strategy that aims to generate trading profit from Intellia Therapeutics as its price is falling. NTLA shares are trading down $0.08 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Intellia Therapeutics? A short squeeze for Intellia Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NTLA, which in turn drives the price of the stock up even further. How often is Intellia Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NTLA, twice per month. The most recent reporting period available is January, 31 2025. More Short Interest Resources from MarketBeat Related Companies SWTX Short Squeeze BHVN Short Squeeze RXRX Short Squeeze PTCT Short Squeeze OGN Short Squeeze RARE Short Squeeze ALVO Short Squeeze RNA Short Squeeze ADMA Short Squeeze ACLX Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NTLA) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellia Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellia Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NTLA Stock Alerts